|
|
Research Pipeline
The Eisai Research Pipeline
|
| Code |
Stage |
Description |
| E5555 |
Phase I
|
Critical care-acute coronary syndrome |
| Aciphex® |
Phase I
|
Gastrointestinal disorder-extended-release formulation |
| E7080 |
Phase I
|
Cancer-oral anti-cancer agent |
| E7974 |
Phase I
|
Cancer |
| E7820 |
Phase I
|
Cancer |
| AS-3201 |
Phase II
|
Diabetic neuropathy |
| E7389 |
Phase II
|
Cancer-non-small cell lung cancer |
| E2007 |
Phase II
|
Neurology-migraine prevention |
| Aciphex® |
Phase II
|
Gastrointestinal disorder-pediatric use |
| Aciphex® |
Phase II
|
Gastrointestinal disorder-intermittent therapy for symptomatic gastroesophageal reflux disease |
| E7389 |
Phase II
|
Breast cancer |
| E2007 |
Phase II
|
Neurology-epilepsy |
| E7389 |
Phase II
|
Prostate cancer |
| E5564 |
Phase III
|
Critical care-severe sepsis |
| Rufinamide |
Submitted to FDA |
Epilepsy- adjunctive therapy for Lennox-Gastaut syndrome in children ages four and over and as therapy for partial-onset seizures with and without secondary generalization in adults and adolescents (12 years of age and over) |
| Aricept® |
Submitted to FDA |
Severe Alzheimer's disease - additional indication |
 Printer Friendly Version
|
|
|
|
Eisai selects research candidates based on their potential to positively impact the health and welfare of patients and caregivers.
|
|
